


BiPar Sciences
Biotechnology Research • South San Francisco, California, United States • 1-10 Employees
Company overview
| Headquarters | Suite 200, South San Francisco, CA 94080, US |
| Phone number | +16506356050 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Oncology |
| Founded | 2004 |
| Employees | 1-10 |
| Socials |
Key Contact at BiPar Sciences
Atul Dhir
Ceo
About BiPar Sciences
BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, including therapy-resistant and difficult-to-treat cancers. BiPar Sciences' lead product candidate, iniparib, the United States Adopted Name (USAN) for the investigational PARP1 inhibitor, BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation. Iniparib significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors. Iniparib is being evaluated in multiple Phase 2 and Phase 3 clinical trials in advanced solid tumors, including triple-negative breast cancer. The company also has two additional compounds in pre-clinical development: BSI-401, a follow-on PARP inhibitor candidate being investigated as an oral therapy for pancreatic cancer, and BSI-302, a novel anti-tubulin therapy
BiPar Sciences revenue & valuation
| Annual revenue | $10,000,000 |
| Revenue per employee | $1,429,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $32,000,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
BiPar Sciences has 3 employees across 3 departments.
Departments
Number of employees
Funding Data
BiPar Sciences has never raised funding before.
Frequently asked questions
4.8
40,000 users



